%0 Journal Article
%A Mai, Elias K
%A Bertsch, Uta
%A Pozek, Ema
%A Fenk, Roland
%A Besemer, Britta
%A Hanoun, Christine
%A Schroers, Roland
%A von Metzler, Ivana
%A Hänel, Mathias
%A Mann, Christoph
%A Leypoldt, Lisa B
%A Heilmeier, Bernhard
%A Huhn, Stefanie
%A Vogel, Sabine K
%A Hundemer, Michael
%A Scheid, Christof
%A Blau, Igor W
%A Luntz, Steffen
%A Weinhold, Niels
%A Tichy, Diana
%A Holderried, Tobias A W
%A Trautmann-Grill, Karolin
%A Gezer, Deniz
%A Klaiber-Hakimi, Maika
%A Müller, Martin
%A Shumilov, Evgenii
%A Knauf, Wolfgang
%A Michel, Christian S
%A Geer, Thomas
%A Riesenberg, Hendrik
%A Lutz, Christoph
%A Raab, Marc S
%A Benner, Axel
%A Hoffmann, Martin
%A Weisel, Katja C
%A Salwender, Hans J
%A Goldschmidt, Hartmut
%T Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
%J Journal of clinical oncology
%V 43
%N 11
%@ 0732-183X
%C Alexandria, Va.
%I American Society of Clinical Oncology
%M DKFZ-2024-02612
%P 1279-1288
%D 2025
%Z 2025 Apr 10;43(11):1279-1288
%X Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a significant increase of minimal residual disease negativity (MRD-) rates after induction therapy. A total of 662 patients were randomly assigned to receive induction therapy with Isa-RVd (n = 331) or RVd (n = 329), followed by single or tandem autologous stem-cell transplant and second random assignment to maintenance with lenalidomide alone or Isa-lenalidomide. We report updated results for part 1 from first random assignment to post-transplant. As of January 31, 2024, MRD- rates continued to deepen after transplant (66
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39652594
%R 10.1200/JCO-24-02266
%U https://inrepo02.dkfz.de/record/294902